Femtosecond Laser-Ablative Aqueous Synthesis of Multi-Drug Antiviral Nanoparticles

16 May 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Nanomedicine offers a number of innovative strategies to address major public health burdens, including influenza and SARS-CoV-2. In this work, we introduce a multi-drug nanoparticle fabricated using femtosecond laser ablation which can be used for the treatment of influenza, SARS-CoV-2, and their co-infections. The influenza antiviral, baloxavir marboxil; the SARS-CoV-2 antiviral, remdesivir; and the anti-inflammatory drug, dexamethasone, were co-ablated in aqueous media, followed by surface modification with a cationic polymer to generate a nanoparticle with a diameter of ~73 nm and a positive zeta potential. We demonstrate high efficacy of these nanoparticles against Influenza Virus A using a clinically relevant, in vitro primary mouse trachea epithelial cell-air-liquid interface culture model. These findings demonstrate great promise both for the use of femtosecond laser ablation to generate multi-drug nanoparticles, as well as for the potential anti-viral effects of our nanoformulation against other respiratory virus infections such as SARS-CoV-2.


Femtosecond Laser Ablation
Air-Liquid Interface
Multi-Drug Nanoparticle

Supplementary materials

Supporting Information
Experimental methods, supporting data including nanoparticle stability studies


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.